| Revenue growth | 6.9% YoY for FY26; non-GPL business grew 13%. |
|---|---|
| Margins | Record 33.6% FY26 EBITDA margin, up 360bps YoY. |
| Order book | Closing 2 new CDMO deals expected in H2 FY27. |
| Demand visibility | Pretty good across regulated markets and CDMO segment. |
| Management confidence | High; confident in sustaining 30-32% margins despite headwinds. |
Growth
FY26 revenue grew 6.9% to ₹2,552cr; PAT stood at ₹565cr with 22.1% margins; EBITDA up 19.6% YoY.
Outlook
Guided 30-32% EBITDA margins; ₹540cr FY27 capex plan; Solapur Phase 1 operational by Q2 FY27.
Risks
Geopolitical conflicts impacting supply chains, elevated logistics/energy costs, and raw material price inflation (solvents).
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹16,766 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.8×Sector 50.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
- Call
- Guides 11% growth
Alivus Life Sciences Investor Presentation: Key Takeaways
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
- Call
- Guides 11% growth
Alivus Life Sciences Q1 FY27 Results: Net Profit ₹160.1 Cr, Up 31.8% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
- Key figure
- Net profit ₹160.1 Cr · +31.8% YoY
Alivus Life Sciences Earnings Call: Key Takeaways
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.